{"id":5852,"date":"2023-03-08T14:46:00","date_gmt":"2023-03-08T14:46:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=5852"},"modified":"2025-01-15T03:04:55","modified_gmt":"2025-01-15T03:04:55","slug":"cost-effectiveness-and-economic-investment-to-eliminate-chronic-hepatitis-c-in-mexico","status":"publish","type":"post","link":"https:\/\/cdafound.org\/es\/cost-effectiveness-and-economic-investment-to-eliminate-chronic-hepatitis-c-in-mexico\/","title":{"rendered":"Costo-efectividad e inversi\u00f3n econ\u00f3mica para eliminar la hepatitis C cr\u00f3nica en M\u00e9xico"},"content":{"rendered":"<h2 class=\"wp-block-heading\" id=\"summary\">Resumen<\/h2>\n\n\n\n<p>En julio de 2020, el gobierno mexicano inici\u00f3 el Programa Nacional para la Eliminaci\u00f3n de la Hepatitis C (VHC) en virtud de un acuerdo de adquisici\u00f3n, asegurando el acceso universal y gratuito a la detecci\u00f3n, el diagn\u00f3stico y el tratamiento del VHC para 2020-2022. Este an\u00e1lisis cuantifica la carga cl\u00ednica y econ\u00f3mica del VHC (MXN) bajo una continuaci\u00f3n (o finalizaci\u00f3n) del acuerdo. Se utiliz\u00f3 un modelo y un enfoque Delphi para evaluar la carga de enfermedad (2020\u20132030) y el impacto econ\u00f3mico (2020\u20132035) de la Base hist\u00f3rica en comparaci\u00f3n con la Eliminaci\u00f3n, suponiendo que el acuerdo contin\u00faa (Eliminaci\u00f3n\u2014Acuerdo hasta 2035) o finaliza (Eliminaci\u00f3n\u2014Acuerdo a 2022). Estimamos los costos acumulados y el gasto de tratamiento por paciente necesario para lograr un costo neto cero (la diferencia en los costos acumulados entre el escenario y la base). La eliminaci\u00f3n se define como una reducci\u00f3n de 90% en nuevas infecciones, 90% cobertura de diagn\u00f3stico, 80% cobertura de tratamiento y 65% reducci\u00f3n de la mortalidad para 2030. Se estim\u00f3 una prevalencia vir\u00e9mica de 0,55% (0,50-0,60) el 1 de enero de 2021, correspondiente a 745.000 (IC 95% 677,000\u2013 812,000) infecciones vir\u00e9micas en M\u00e9xico. El Acuerdo de Eliminaci\u00f3n hasta 2035 lograr\u00eda un costo neto cero para 2023 y acumular\u00eda 31.200 millones en costos acumulados. Los costos acumulativos bajo el Acuerdo de Eliminaci\u00f3n hasta 2022 se estiman en 74,2 mil millones. Bajo el Acuerdo de Eliminaci\u00f3n hasta el 2022, el precio del tratamiento por paciente debe disminuir a 11,000 para lograr un costo neto cero para el 2035. El gobierno mexicano podr\u00eda extender el acuerdo hasta el 2035 o reducir el costo del tratamiento del VHC a 11,000 para lograr la eliminaci\u00f3n del VHC al 2035. -coste cero.<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/cdafound.org\/wp-content\/uploads\/2023\/06\/Mooneyhan-2023-Cost-effectiveness-and-economic-investment-to-eliminate-CHC-in-Mexico.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Lea el informe completo<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary In July 2020, the Mexican Government initiated the National Program for Elimination of Hepatitis C (HCV) under a procurement agreement, securing universal, free access to HCV screening, diagnosis and treatment for 2020\u20132022. This analysis quantifies the clinical and economic burden of HCV (MXN) under a continuation (or end) to the agreement. A modelling and [&hellip;]<\/p>\n","protected":false},"author":939,"featured_media":3193,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[32,10,12],"publication-author":[128,126,130,90,97,92,127,129],"class_list":["post-5852","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-economic-impact","tag-hcv","tag-modelling","publication-author-alethse-de-la-torre-rosas","publication-author-daniel-bernal-serrano","publication-author-david-kershenobich","publication-author-ellen-mooneyhan","publication-author-homie-razavi","publication-author-ivane-gamkrelidze","publication-author-leandro-sereno","publication-author-maria-jesus-sanchez"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/5852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/users\/939"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/comments?post=5852"}],"version-history":[{"count":4,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/5852\/revisions"}],"predecessor-version":[{"id":7518,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/5852\/revisions\/7518"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media\/3193"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media?parent=5852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/categories?post=5852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/tags?post=5852"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/publication-author?post=5852"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}